Spero Therapeutics (SPRO) Receiving Somewhat Favorable News Coverage, Report Shows
Media coverage about Spero Therapeutics (NASDAQ:SPRO) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spero Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.8816789399444 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Spero Therapeutics (NASDAQ:SPRO) traded up $0.08 during trading on Tuesday, reaching $10.04. The company had a trading volume of 24,200 shares, compared to its average volume of 25,863. Spero Therapeutics has a 1 year low of $9.66 and a 1 year high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.43) by ($33.59). The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $0.20 million. equities analysts anticipate that Spero Therapeutics will post -8.52 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Spero Therapeutics (SPRO) Receiving Somewhat Favorable News Coverage, Report Shows” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2018/02/20/spero-therapeutics-spro-receiving-somewhat-favorable-news-coverage-report-shows.html.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.